The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review.

Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. · 2008

Read The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. by Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2228386.txt.

Description

Cramer and colleagues reviewed medication adherence studies in 2008 for diabetes, hypertension and abnormal blood lipids. Patients often stop or skip long-term cardiovascular and diabetes drugs, weakening treatment. The team searched major databases for English-language studies from 2000 to 2005. They compared how 139 studies defined and measured compliance and persistence, and whether adherence tracked with clinical outcomes.

The commonest measure was the twelve-month medication possession ratio, averaging 72 percent overall. It barely differed between drug classes, ranging from 67 to 76 percent across them. Only 59 percent of patients covered over 80 percent of their days with medication. That coverage level is a standard threshold for good adherence in these studies. Twelve-month persistence averaged 63 percent. Good compliance improved outcomes in 73 percent of studies that checked.

Catalog record

CREATORCramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE64 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2228386

Browse the full library · About the Tower of Babel